Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice

• Päätekijät: Abduzhappar Gaipov (Tekijä), Alpamys Issanov (Tekijä), Zhanar Mursalova (Tekijä), Nazia Tulegenova (Tekijä), Zoya Kakim (Tekijä), Mukhit Baizakov (Tekijä), Saltanat Tuganbekova (Tekijä), Mohamad Aljofan (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Wiley, 2020-06-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract Recently, biosimilar erythropoietin stimulating agents become available in Kazakhstan. Important properties of the biosimilar such as dose equivalency to the original medicine (originator) and the ability to maintain hemoglobin target levels remain insufficiently described in many clinical...